Racial or ethnic differences on treatment adherence and persistence among patients with inflammatory bowel diseases initiated with biologic therapies

Table 2 Multivariate analysis for treatment adherence and discontinuation in patients with CD or UC

Parameters	12-month Adherence		Time-to-discontinuation during follow-up
Parameters	Unadjusted OR (95% CI)	Adjusted OR^a (95% CI)	Unadjusted HR (95% CI)	Adjusted HR^a (95% CI)
CD	n = 916		n = 1250
African American vs White	0.55 (0.36; 0.86)	0.61 (0.38; 0.99)	1.75 (1.36; 2.26)	1.52 (1.16; 2.00)
Asian vs White	1.11 (0.48; 2.60)	0.97 (0.41; 2.32)	1.04 (0.60; 1.80)	1.25 (0.71; 2.20)
Hispanic vs White	0.70 (0.40; 1.23)	0.70 (0.39; 1.29)	1.15 (0.79; 1.67)	1.10 (0.75; 1.61)
UC	n = 682		n = 934
African American vs White	1.20 (0.68; 2.14)	1.45 (0.78; 2.71)	0.99 (0.71; 1.39)	1.00 (0.71; 1.42)
Asian vs White	0.73 (0.29; 1.89)	0.56 (0.20; 1.56)	0.80 (0.41; 1.55)	0.83 (0.42; 1.63)
Hispanic vs White	0.93 (0.53; 1.64)	0.85 (0.47; 1.55)	1.00 (0.72; 1.39)	1.14 (0.81; 1.60)

CD Crohn’s disease, CI Confidence interval, OR Odds ratio, HR Hazard ratio, UC Ulcerative colitis
Multivariate analysis for treatment adherence and discontinuation was performed in patients with non-missing household income
^a Other variables adjusted in the regression models include baseline clinical and sociodemographic characteristics including age, sex, education level, income, insurance plan type, hypertension, nausea and vomiting, anemia, rheumatoid arthritis, psoriasis, psoriatic arthritis, surgery, opioid use, steroid use, immunomodulators

ISSN: 1471-230X